Raymond James Financial Inc. Takes $3.23 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Raymond James Financial Inc. acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 82,095 shares of the company's stock, valued at approximately $3,231,000. Raymond James Financial Inc. owned about 0.10% of CRISPR Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in CRSP. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics in the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP raised its position in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $40,000. Spire Wealth Management boosted its holdings in shares of CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $80,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Greene bought 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now directly owns 7,000 shares of the company's stock, valued at $313,950. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 32,381 shares of company stock worth $1,608,243 over the last quarter. Insiders own 4.10% of the company's stock.

Remove Ads

CRISPR Therapeutics Stock Down 8.0 %

Shares of NASDAQ CRSP traded down $2.96 during midday trading on Monday, reaching $34.03. 3,968,336 shares of the company's stock traded hands, compared to its average volume of 1,561,284. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -7.79 and a beta of 1.77. The stock's 50 day simple moving average is $42.97 and its 200-day simple moving average is $45.09. CRISPR Therapeutics AG has a one year low of $32.98 and a one year high of $68.39.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on CRSP shares. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective for the company in a research note on Wednesday, February 12th. Barclays lifted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Royal Bank of Canada reduced their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 12th. JMP Securities restated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Finally, The Goldman Sachs Group reduced their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.